Table 1.
Baseline characteristics of patients with SCAP.
| Cefoperazone-sulbactam N = 343 | Piperacillin-tazobactam N = 472 | P value | |
|---|---|---|---|
| Age (yr) Mean ± SD | 74.78 ± 15.00 | 75.14 ± 14.20 | .874 |
| Gender, Male (%) | 242 (70.6%) | 339 (71.8%) | .696 |
| Treatment d Mean ± SD | 9.08 ± 3.53 | 9.31 ± 3.75 | .462 |
| Pathogens, n (%) | |||
| Escherichia coli | 18 (5.2%) | 34 (7.2%) | .325 |
| Klebsiella pneumoniae | 38 (11.1%) | 39 (8.2%) | .216 |
| Pseudomonas aeruginosa | 22 (6.4%) | 41 (8.6%) | .286 |
| Acinetobacter spp. | 20 (5.8%) | 21 (4.4%) | .466 |
| Streptococcus | 19 (5.5%) | 20 (4.2%) | .487 |
| Other pathogens | 50 (14.5%) | 74 (15.6%) | .739 |
| No growth/NA | 176 (51.3%) | 243 (51.4%) | .981 |
| Charlson score, Mean ± SD | 6.20 ± 2.77 | 5.72 ± 2.61 | .009* |
| PSI score, Mean ± SD | 146.89 ± 45.34 | 146.63 ± 43.08 | .651 |
| Curb-65 score, Mean ± SD | 2.65 ± 1.23 | 2.60 ± 1.30 | .649 |
| In-hospital mortality, n (%) | 55 (16.0%) | 84 (17.8%) | .572 |
| Primary outcome, n (%) | .367 | ||
| Clinical cure | 287 (84.2%) | 378 (80.3%) | |
| Failure/Indeterminate | 54 (15.7%) | 93 (19.7%) | |
| Secondary outcome, n (%) | .258 | ||
| Effective | 293 (85.4%) | 393 (83.3%) | |
| Ineffective/Indeterminate | 50 (14.5%) | 79(16.7%) | |
| INR before medicine, n | 29 | 11 | .296 |
| Median (95% CI) | 1.14 (1.07, 1.19) | 1.10 (0.90, 1.82) | |
| INR after medicine, n | 21 | 6 | .579 |
| Median (95% CI) | 1.13 (1.09, 1.25) | 1.06 (0.94, 1.33) | |
CI = confidence interval, INR = international normalized ratio, PSI = pneumonia severity index, SCAP = severe community acquired pneumonia, SD = standard deviation.
*
P < 0.05.